Insmed's lung disease drug succeeds in late-stage study
Send a link to a friend
[May 28, 2024]
(Reuters) - Insmed said its experimental drug to treat a type of
chronic lung disease helped significantly reduce respiratory symptoms
such as chronic cough in a late-stage study, prompting its shares to
double in premarket trading on Tuesday.
The drug candidate, brensocatib, is being developed to treat patients
with non-cystic fibrosis bronchiectasis, a chronic lung condition where
the walls of the airways are widened due to inflammation and infection.
Bronchiectasis affects about 450,000 patients in the United States, and
causes symptoms including excessive sputum production, shortness of
breath, and repeated respiratory infections, according to Insmed.
[to top of second column]
|
![](http://archives.lincolndailynews.com/2024/May/28/images/ads/current/bennet_lda_010722.png) The company said it plans to file a
marketing application for brensocatib with the U.S. Food and Drug
Administration in the fourth quarter of this year, and it expects to
launch the drug in mid-2025.
(Reporting by Mariam Sunny in Bengaluru; Editing by Krishna Chandra
Eluri and Shinjini Ganguli)
[© 2024 Thomson Reuters. All rights reserved.]This material may not be published,
broadcast, rewritten or redistributed.
Thompson Reuters is solely responsible for this content. |